CJC-1295: half-life chemistry and DAC vs no-DAC research

CJC-1295 is the GHRH(1–29) analog where the design conversation gets interesting. It comes in two distinct molecular forms — with and without a Drug Affinity Complex (DAC) — that produce radically different pharmacokinetic profiles despite hitting the same receptor. Understanding the difference is the entire point of working with this compound; treating "CJC-1295" as one thing leads to study-design errors that show up in the data.

The shared backbone: four substitutions on GHRH(1–29)

Both forms share the same 29-amino-acid backbone — a sermorelin-class GHRH(1–29) sequence with four substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These changes confer resistance to dipeptidyl peptidase-IV cleavage (the substitution at position 2 is the key one) and to other proteolytic clearances that destroy native sermorelin in ~6.5 minutes^[1].

Without DAC, this stabilized GHRH(1–29) — sometimes sold as "Mod GRF 1-29" or "CJC-1295 without DAC" — has a plasma half-life on the order of 30 minutes. Long enough to produce a meaningful pulsatile GH spike when administered, short enough that the GHRH-R returns to a basal state between doses. The receptor pharmacology is otherwise identical to sermorelin's: Gαs / cAMP / PKA at the pituitary somatotrope.

The DAC modification

The "with DAC" form attaches a maleimidopropionic acid (MPA) linker to the C-terminus that covalently binds to a cysteine residue on circulating albumin in vivo. The peptide is essentially synthesized with a small reactive handle; once injected, it finds an albumin molecule, forms a covalent bond, and rides circulation as part of the much larger albumin complex. This pushes the half-life from ~30 minutes to roughly 6–8 days in human pharmacokinetic studies^[2].

The Teichman 2006 paper in JCEM is the canonical reference for the DAC pharmacology: in the published study, sustained elevation of GH and IGF-1 was observed over multiple weeks, with measurable receptor engagement across the exposure window^[2]. X Factor provides no dosing, protocol, or use-window guidance; this is research-literature context only.

The mechanistic problem with DAC: continuous agonism

This is where CJC-1295 becomes pharmacologically interesting and operationally controversial. The pituitary GHRH-R is designed for pulsatile signaling. Native GHRH is secreted in bursts; the receptor down-regulates and re-sensitizes between pulses. The somatotrope's GH transcription program is fundamentally tuned to this pulsatile input.

CJC-1295 with DAC delivers continuous receptor agonism — albumin-bound peptide is present in circulation 24 hours a day for the entire dosing week. The published data show this works in the short term but raises an open question about long-term somatotrope responsiveness. Independent groups (Ionescu 2006, Sackmann-Sala 2014) have documented attenuation of pulsatile GH response and partial GHRH-R desensitization under sustained CJC-1295/DAC administration^[3][4].

"The DAC modification solves a pharmacokinetic problem and creates a pharmacodynamic one. The receptor is engineered for pulses. CJC-1295/DAC gives it a continuous signal. Whether the trade is net positive depends entirely on the research question being asked."

Why this matters for study design

If your protocol is studying acute GHRH-R signaling, CJC-1295 without DAC is the right tool. The pulsatile signaling resembles physiologic GHRH and avoids the down-regulation confound. If your protocol is studying long-term IGF-1 elevation as an endpoint without caring about pulsatility, CJC-1295 with DAC is the convenience choice. A protocol that conflates the two will produce contradictory data.

What the RUO market typically ships

Most RUO suppliers — X Factor included — ship CJC-1295 without DAC by default, sometimes labeled as "Mod GRF 1-29" or just "CJC-1295." The DAC form is less commonly available and is more expensive to synthesize due to the maleimido linker chemistry. If your protocol specifically requires DAC, confirm with the supplier before ordering. The Mod GRF / no-DAC form is what's in the X Factor catalog as "CJC-1295".

What the literature does NOT show

• No registered clinical indication. Unlike tesamorelin (which made it to FDA approval for HIV-lipodystrophy), CJC-1295 in either form has not reached an approved indication. The development program effectively stalled after the Teichman / ConjuChem work.
• Cardiovascular safety signal under DAC. Some early development was discontinued after a fatal cardiac event in a clinical study. Whether this was drug-attributable or coincidental remains debated. Anyone working with the DAC form should be aware of this history.
• Pulsatility advantage is theoretical. The argument that pulsatile GHRH analogs (sermorelin, CJC-no-DAC, tesamorelin) are "better" than continuous ones is mechanistically grounded but not proven in head-to-head clinical comparisons.

How a careful researcher orders CJC-1295

• Confirm DAC status. Ask the supplier explicitly. The two forms are distinct compounds despite sharing a backbone.
• HPLC + LC-MS per lot. Mass-spec confirmation should appear at ~3367 Da monoisotopic for the no-DAC form, ~3647 Da for the DAC form.
• Storage at -20°C, light-protected. The maleimide linker on the DAC form is reactive — light and oxygen exposure accelerates degradation.
• Reconstitution in bacteriostatic water at neutral pH. The DAC form is especially sensitive to acidic pH.

X Factor ships the no-DAC form. The lot COA in the public library explicitly notes the form supplied.

References

1. Jetté L et al., 2005 — Drug Affinity Complex (DAC) technology for sustained GHRH receptor agonism, Endocrinology.
2. Teichman SL et al., 2006 — Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, J Clin Endocrinol Metab.
3. Ionescu M & Frohman LA, 2006 — Pulsatile secretion of GH stimulated by continuous administration of a GHRH analog, J Clin Endocrinol Metab.
4. Sackmann-Sala L et al., 2014 — Desensitization of the GHRH receptor under continuous agonism, Endocrinology.
5. Walker RF, 1991 — Sermorelin: a better approach to GH research?, Drugs Aging.
6. Falutz J et al., 2007 — Tesamorelin and visceral adipose research (comparator for stabilized GHRH analogs), NEJM.

Research use only. Not medical advice. CJC-1295 is not approved by the FDA for any human or veterinary use. Citations are linked directly to PubMed.